{
  "main_header": {
    "sid": 417872,
    "name": "Boston Bio",
    "stock_name": "Boston Bio",
    "full_name": "Boston Bio Systems Ltd",
    "name_url": "stocks-analysis/boston-bio",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "7.01",
    "chg": -0.34,
    "chgp": "-4.63%",
    "dir": -1,
    "prev_price": "7.35",
    "mcapval": "4.91 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531458,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 26,
    "indexname": "",
    "isin": "INE109B01019",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1 ",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/boston-bio-417872-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Boston Bio?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-boston-bio-3704049",
        "imagepath": "",
        "date": "2025-11-15 00:23:21",
        "description": "Answer:\nThe historical performance of Boston Bio shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.\n\nBreakdown:\nBoston Bio's net sales have seen a notable decline from 1.50 Cr in March 2016 to just 0.19 Cr in March 2025, with a complete absence of sales in the intervening years of March 2017, March 2018, and March 2024. The total operating income followed a similar trend, peaking at 1.50 Cr in March 2016 and dropping to 0.19 Cr in March 2025. The company has consistently reported no raw material costs or purchase of finished goods, indicating a lack of production activity. Total expenditure, however, increased to 0.74 Cr in March 2025, up from 0.14 Cr in March 2024, primarily driven by other expenses. This led to an operating profit (PBDIT) of -0.55 Cr in March 2025, reflecting a negative operating profit margin of -289.47%. The profit before..."
      },
      {
        "title": "Why is Boston Bio falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-boston-bio-fallingrising-3681594",
        "imagepath": "",
        "date": "2025-11-08 00:04:20",
        "description": "As of 07-Nov, Boston Bio Systems Ltd is experiencing a decline in its stock price, currently at 7.75, which represents a decrease of 0.37 or 4.56%. The stock has been underperforming, having fallen consecutively for the last two days and showing a total return of -8.82% over the past week. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. There has also been a significant drop in investor participation, with delivery volume on 06 Nov falling by 59.78% compared to the 5-day average. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Boston Bio's short-term performance has significantly lagged behind the benchmark, the Sensex, which has only decreased by 0.86% over the same week. While the Sensex has sho..."
      }
    ],
    "total": 66,
    "sid": "417872",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/boston-bio-systems-417872"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Jan-2026",
      "details": "Certificate under Regulation 74(5) of SEBI(Depositories and Participants)Regulations 2018 for the quarter ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Dec-2025",
      "details": "Closure of Trading Window from 1st January 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change of Company Name",
      "datetime": "27-Nov-2025",
      "details": "Intimation under Regulation 30 of the SEBI (LODR) Regulation 2015 - Change in the Name of the Company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Boston Bio?

2025-11-15 00:23:21

Answer: The historical performance of Boston Bio shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability. Breakdown: Boston Bio's net sales have seen a notable decline from 1.50 Cr in March 2016 to just 0.19 Cr in March 2025, with a complete absence of sales in the intervening years of March 2017, March 2018, and March 2024. The total operating income followed a similar trend, peaking at 1.50 Cr in March 2016 and dropping to 0.19 Cr in March 2025. The company has consistently reported no raw material costs or purchase of finished goods, indicating a lack of production activity. Total expenditure, however, increased to 0.74 Cr in March 2025, up from 0.14 Cr in March 2024, primarily driven by other expenses. This led to an operating profit (PBDIT) of -0.55 Cr in March 2025, reflecting a negative operating profit margin of -289.47%. The profit before...

Read More

Why is Boston Bio falling/rising?

2025-11-08 00:04:20

As of 07-Nov, Boston Bio Systems Ltd is experiencing a decline in its stock price, currently at 7.75, which represents a decrease of 0.37 or 4.56%. The stock has been underperforming, having fallen consecutively for the last two days and showing a total return of -8.82% over the past week. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. There has also been a significant drop in investor participation, with delivery volume on 06 Nov falling by 59.78% compared to the 5-day average. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Boston Bio's short-term performance has significantly lagged behind the benchmark, the Sensex, which has only decreased by 0.86% over the same week. While the Sensex has sho...

Read More

View All News